Capstan Therapeutics develops targeted lipid nanoparticles (tLNPs) that deliver mRNA and gene editing tools to specific cell types in vivo, enabling precise reprogramming of cells for therapeutic purposes. This technology addresses the need for effective treatments across various diseases, including oncology and genetic disorders, by facilitating safe and repeatable dosing with tailored payloads.
Funding
$340M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current therapeutic approaches for various diseases, including oncology and genetic disorders, often lack the precision needed to target specific cell types within the body. Systemic treatments can lead to off-target effects and toxicities, limiting their efficacy and safety. Effective and repeatable dosing remains a challenge in many therapeutic areas.
Solution
Capstan Therapeutics develops targeted lipid nanoparticles (tLNPs) designed to deliver mRNA and gene editing tools directly to specific cell types in vivo. The company's CellSeeker™ platform utilizes LNPs conjugated with recombinant protein binders, such as monoclonal antibodies, to achieve precise targeting. This approach enables the reprogramming of cells for therapeutic purposes, offering a modular therapeutic product design with a toolbox of tLNP constructs and a broad range of payloads. Capstan's technology supports repeat dosing and drug-like pharmacokinetics, with the potential for administration in earlier disease stages and outpatient settings. The platform can be used to engineer immune cells by delivering mRNA-encoded CARs or to target pathogenic cells by delivering mRNA-encoded gene editing machinery.
Target Audience
Capstan's primary target audience includes researchers and clinicians focused on developing targeted therapies for oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.
Features
- Proprietary lipid nanoparticle (LNP) system designed for safe, repeat in vivo dosing
- Cell type-specific targeting binders, including antibody or antibody fragments functionalized onto the nanoparticle surface
- Disease-specific payloads, such as mRNA encoding for Chimeric Antigen Receptors (CARs) and gene editing machinery
- Tunable platform to fit safety and efficacy requirements depending on disease indication
- Scalable manufacturing processes
- Potential for cell type-specific targeting of disease-relevant cells
- Modular therapeutic product design with a toolbox of tLNP constructs and a broad range of payloads